Crucell and NIH extend Ebola Vaccine Agreement
Crucell N.V. announced that it has extended its Cooperative Research and Development Agreement (CRADA) with the Vaccine Research Center (VRC), part of the National Institute of Allergy and infectious diseases (NIAID) of the National Institutes of Health (NIH), for the development of vaccines to protect against Ebola, Marburg and Lassa infections.
Under the existing CRADA, Crucell and the VRC have developed a PER.C6®-based Ebola vaccine which is undergoing pre-clinical evaluation. In the extended CRADA, Crucell and the VRC will continue to develop this vaccine and will use the Ebola vaccine results in the development of Marburg and Lassa vaccines.
Under the terms of the agreement, the NIAID will provide funding for the experiments performed at the VRC and for animal studies, which will be performed at the US Army Medical Research Institute of Infectious Diseases (USAMRIID). Crucell has the option for exclusive commercialisation rights to any intellectual property generated by the VRC on the Ebola, Marburg and Lassa vaccines that falls under theresearch plan of this CRADA.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
LibraGen signs partnership agreement with Pierre Fabre Medicament R&D - LibraGen will use its industrial biocatalysis know-how to carry out research into optimizing the synthesis of a pharmaceutical molecule
Heptares secures £21 million in Series A fund raising - Funds to accelerate development of pipeline of small molecules against high-value GPCR drug targets
Auspherix Raises £6Million to Progress its Novel Antibiotics and Establishes UK Operations
CEO of LTS Lohmann Therapie-Systeme AG retires
Ablynx's anti-vWF Nanobody achieves clinical proof-of-concept in Phase II TITAN study - First-in-class potential with orphan drug status for the treatment of acquired thrombotic thrombocytopenic purpura
Sanofi-aventis, Innogenetics, and Inserm to collaborate on Alzheimer's disease
From bacteria to electricity: The future of green energy

Cube Biotech acquires IBA Lifesciences - Two leading innovators of biotech join forces
